State Street SPDR S&P Biotech ETF XBI

Zacks Investment Research 11 nov

First Trust NYSE Arca Biotechnology ETF (FBT) is a smart beta ETF with $3.03 billion in assets that has delivered strong performance, gaining 31.51% year-to-date and 38.22% over the past year. However, it carries higher risk with a standard deviation of 20.96% and concentrated exposure with only 31 holdings. The ETF charges a competitive 0.55% expense ratio and focuses entirely on healthcare/biotechnology companies.

The Motley Fool 7 nov

The article compares two healthcare ETFs: RSPH (Invesco S&P 500 Equal Weight Healthcare ETF) and XBI (State Street SPDR S&P Biotech ETF). RSPH offers broader healthcare sector diversification with lower volatility and higher dividend yield (0.56%), while XBI provides concentrated biotech exposure with higher short-term returns (39.6% 1-year) but steeper drawdowns (53.2% max). RSPH is recommended for conservative investors seeking stability, while XBI suits those with higher risk tolerance seeking biotech-specific growth.

Zacks Investment Research 4 nov

The First Trust NYSE Arca Biotechnology ETF (FBT) is reviewed as a passively managed fund offering broad exposure to the biotech sector with $3.1 billion in assets. The ETF has delivered strong year-to-date performance of 33.68% and one-year returns of 43.62%, though it carries higher risk with a beta of 0.68 and standard deviation of 20.77%. FBT received a Zacks ETF Rank of 2 (Buy) and is compared to competitors XBI and IBB, which have larger asset bases and lower expense ratios.

Zacks Investment Research 2 nov

The iShares Biotechnology ETF (IBB) is a smart beta ETF with $11.32 billion in assets that tracks the Nasdaq Biotechnology Index. With a 0.44% expense ratio and 248 holdings, it offers diversified exposure to biotech and pharmaceutical companies. The fund has returned 29.03% year-to-date and 38.55% over the past year, but carries higher risk with a beta of 0.70 and 20.96% standard deviation. Alternative biotech ETFs like FBT and XBI are also available for comparison.

Zacks Investment Research 26 oct

The State Street SPDR S&P Biotech ETF (XBI) is reviewed as a passively managed fund with low costs (0.35% expense ratio) and $10.42 billion in assets. The ETF has delivered strong year-to-date returns of 22.76% and 12-month returns of 39.54%, though it carries high risk with a beta of 0.83 and 27.66% standard deviation. With 167 holdings and a Zacks ETF Rank of 3 (Hold), it offers diversified biotech exposure but faces competition from similar alternatives like IBB and FBT.